Cargando...
Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen
OBJECTIVE: Tamoxifen is used as a complementary treatment for estrogen receptor (ER)-positive breast cancer (BCa), but many patients developed resistance. The aim of this study was to examine the role of syndecan-binding protein (SDCBP) silencing in ER-positive BCa cells. METHODS: In MCF-7/T47D cell...
Gardado en:
| Publicado en: | Cancer Biol Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Chinese Anti-Cancer Association
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5842332/ https://ncbi.nlm.nih.gov/pubmed/29545966 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20892/j.issn.2095-3941.2017.0122 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|